| Summary: | Glioblastoma (GBM) is one of the most aggressive tumors and its 5-year survival is approximately 5%. Fluorescence-guided surgery (FGS) improves the extent of resection and leads to better prognosis. Molecular near-infrared (NIR) imaging appears to outperform conventional FGS, however, novel molecular targets need to be identified in GBM. Proteoglycan glypican-1 (GPC-1) is believed to be such a target as it is highly expressed in GBM and is associated with poor prognosis. We hypothesize that an anti-GPC-1 antibody, Miltuximab<sup>®</sup>, conjugated with the NIR dye, IRDye800CW (IR800), can specifically accumulate in a GBM xenograft and provide high-contrast in vivo fluorescent imaging in rodents following systemic administration. Miltuximab<sup>®</sup> was conjugated with IR800 and intravenously administered to BALB/c nude mice bearing a subcutaneous U-87 GBM hind leg xenograft. Specific accumulation of Miltuximab<sup>®</sup>-IR800 in subcutaneous xenograft tumor was detected 24 h later using an in vivo fluorescence imager. The conjugate did not cause any adverse events in mice and caused strong fluorescence of the tumor with tumor-to-background ratio (TBR) reaching 10.1 ± 2.8. The average TBR over the 10-day period was 5.8 ± 0.6 in mice injected with Miltuximab<sup>®</sup>-IR800 versus 2.4 ± 0.1 for the control group injected with IgG-IR800 (<i>p</i> = 0.001). Ex vivo assessment of Miltuximab<sup>®</sup>-IR800 biodistribution confirmed its highly specific accumulation in the tumor. The results of this study confirm that Miltuximab<sup>®</sup>-IR800 holds promise for intraoperative fluorescence molecular imaging of GBM and warrants further studies.
|
|---|
